Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21

Journal of Biological Chemistry

Volumn 291, Issue 11, 2016, Pages 5986-5996

  Dunshee, Diana Ronai ^a   Bainbridge, Travis W ^a   Kljavin, Noelyn M ^a   Zavala Solorio, Jose ^a   Schroeder, Amy C ^a   Chan, Ruby ^a   Corpuz, Racquel ^a   Wong, Manda ^a   Zhou, Wei ^a   Deshmukh, Gauri ^a   Ly, Justin ^a   Sutherlin, Daniel P ^a   Ernst, James A ^a   Sonoda, Junichiro ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CHEMICAL ACTIVATION; NUTRITION; PROTEINS;

CHEMICAL INHIBITORS; CYNOMOLGUS MONKEYS; FIBROBLAST GROWTH FACTOR; HEPATOPROTECTIVE; METABOLIC DISORDERS; NON-ALCOHOLIC STEATOHEPATITIS; PROTEOLYTIC CLEAVAGE; TYPE-2 DIABETES;

FIBROBLASTS;

FIBROBLAST GROWTH FACTOR 21; SEPRASE; FIBROBLAST GROWTH FACTOR; GELATINASE; MEMBRANE PROTEIN; RECOMBINANT PROTEIN; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EX VIVO STUDY; FAP GENE; GENE; GENE DELETION; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; GENETICS; HEK293 CELL LINE; HUMAN; KNOCKOUT MOUSE; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; FIBROBLAST GROWTH FACTORS; GELATINASES; GENE DELETION; HEK293 CELLS; HUMANS; MACACA FASCICULARIS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PROTEOLYSIS; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES;

EID: 84973340534     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.710582     Document Type: Article

References (52)

1. Shulman, G. I. (2014) Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med. 371, 1131-1141
2. Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., Abraham, J. P., Abu-Rmeileh, N. M., Achoki, T., AlBuhairan, F. S., and Alemu, Z. A., et al. (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384, 766-781
3. Owen, B. M., Mangelsdorf, D. J., and Kliewer, S. A. (2015) Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol. Metab. 26, 22-29
4. Gimeno, R. E., and Moller, D. E. (2014) FGF21-based pharmacotherapy: potential utility for metabolic disorders. Trends Endocrinol. Metab. 25, 303-311
5. Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., and Kharitonenkov, A. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149, 6018-6027
6. Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y. S., Lindberg, R. A., Chen, J. L., Jung, D. Y., Zhang, Z., Ko, H. J., Kim, J. K., and Véniant, M. M. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250-259
7. Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., and Spiegelman, B. M. (2012) FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26, 271-281
8. Fisher, F. M., Chui, P. C., Nasser, I. A., Popov, Y., Cunniff, J. C., Lundasen, T., Kharitonenkov, A., Schuppan, D., Flier, J. S., and Maratos-Flier, E. (2014) Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 147, 1073-1083.e6
9. Jiang, S., Yan, C., Fang, Q. C., Shao, M. L., Zhang, Y. L., Liu, Y., Deng, Y. P., Shan, B., Liu, J. Q., Li, H. T., Yang, L., Zhou, J., Dai, Z., Liu, Y., and Jia, W. P. (2014) Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J. Biol. Chem. 289, 29751-29765
10. Lin, Z., Tian, H., Lam, K. S., Lin, S., Hoo, R. C., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., and Li, X. (2013) Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17, 779-789
11. Holland, W. L., Adams, A. C., Brozinick, J. T., Bui, H. H., Miyauchi, Y., Kusminski, C. M., Bauer, S. M., Wade, M., Singhal, E., Cheng, C. C., Volk, K., Kuo, M. S., Gordillo, R., Kharitonenkov, A., and Scherer, P. E. (2013) An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 17, 790-797
12. Laeger, T., Henagan, T. M., Albarado, D. C., Redman, L. M., Bray, G. A., Noland, R. C., Münzberg, H., Hutson, S. M., Gettys, T. W., Schwartz, M. W., and Morrison, C. D. (2014) FGF21 is an endocrine signal of protein restriction. J. Clin. Invest. 124, 3913-3922
13. Kim, S. H., Kim, K. H., Kim, H. K., Kim, M. J., Back, S. H., Konishi, M., Itoh, N., and Lee, M. S. (2015) Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia 58, 809-818
14. Tanaka, N., Takahashi, S., Zhang, Y., Krausz, K. W., Smith, P. B., Patterson, A. D., and Gonzalez, F. J. (2015) Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet. Biochim. Biophys. Acta 1852, 1242-1252
15. Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., and Moller, D. E. (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333-340
16. Dong, J. Q., Rossulek, M., Somayaji, V. R., Baltrukonis, D., Liang, Y., Hudson, K., Hernandez-Illas, M., and Calle, R. A. (2015) Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Br. J. Clin. Pharmacol. 80, 1051-1063
17. Gälman, C., Lundåsen, T., Kharitonenkov, A., Bina, H. A., Eriksson, M., Hafström, I., Dahlin, M., Amark, P., Angelin, B., and Rudling, M. (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell Metab. 8, 169-174
18. Zhang, X., Yeung, D. C., Karpisek, M., Stejskal, D., Zhou, Z.-G., Liu, F., Wong, R. L., Chow, W.-S., Tso, A. W., Lam, K. S., and Xu, A. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57, 1246-1253
19. Chen, W. W., Li, L., Yang, G. Y., Li, K., Qi, X. Y., Zhu, W., Tang, Y., Liu, H., and Boden, G. (2008) Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 116, 65-68
20. Mraz, M., Bartlova, M., Lacinova, Z., Michalsky, D., Kasalicky, M., Haluzikova, D., Matoulek, M., Dostalova, I., Humenanska, V., and Haluzik, M. (2009) Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin. Endocrinol. (Oxf) 71, 369-375
21. Yan, H., Xia, M., Chang, X., Xu, Q., Bian, H., Zeng, M., Rao, S., Yao, X., Tu, Y., Jia, W., and Gao, X. (2011) Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS ONE 6, e24895
22. Markan, K. R., Naber, M. C., Ameka, M. K., Anderegg, M. D., Mangelsdorf, D. J., Kliewer, S. A., Mohammadi, M., and Potthoff, M. J. (2014) Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63, 4057-4063
23. Patel, R., Bookout, A. L., Magomedova, L., Owen, B. M., Consiglio, G. P., Shimizu, M., Zhang, Y., Mangelsdorf, D. J., Kliewer, S. A., and Cummins, C. L. (2015) Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. Mol. Endocrinol. 29, 213-223
24. Kharitonenkov, A., Beals, J. M., Micanovic, R., Strifler, B. A., Rathnachalam, R., Wroblewski, V. J., Li, S., Koester, A., Ford, A. M., Coskun, T., Dunbar, J. D., Cheng, C. C., Frye, C. C., Bumol, T. F., and Moller, D. E. (2013) Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE 8, e58575
25. Yie, J., Hecht, R., Patel, J., Stevens, J., Wang, W., Hawkins, N., Steavenson, S., Smith, S., Winters, D., Fisher, S., Cai, L., Belouski, E., Chen, C., Michaels, M. L., Li, Y.-S., Lindberg, R., Wang, M., Véniant, M., and Xu, J. (2009) FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 583, 19-24
26. Micanovic, R., Raches, D. W., Dunbar, J. D., Driver, D. A., Bina, H. A., Dickinson, C. D., and Kharitonenkov, A. (2009) Different roles of N- and C- termini in the functional activity of FGF21. J. Cell. Physiol. 219, 227-234
27. Hecht, R., Li, Y. S., Sun, J., Belouski, E., Hall, M., Hager, T., Yie, J., Wang, W., Winters, D., Smith, S., Spahr, C., Tam, L. T., Shen, Z., Stanislaus, S., Chinookoswong, N., Lau, Y., Sickmier, A., Michaels, M. L., Boone, T., Véniant, M. M., and Xu, J. (2012) Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS ONE 7, e49345
28. Umberger, T. S., Sloan, J. H., Chen, J., Cheng, C., Siegel, R. W., Qian, Y., Troutt, J. S., and Konrad, R. J. (2014) Novel sandwich immunoassays for the measurement of total and active FGF21. Bioanalysis 6, 3283-3293
29. Drucker, D. J., and Nauck, M. A. (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705
30. Lee, K. N., Jackson, K. W., Christiansen, V. J., Lee, C. S., Chun, J. G., and McKee, P. A. (2006) Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 107, 1397-1404
31. Liu, R., Li, H., Liu, L., Yu, J., and Ren, X. (2012) Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol. Ther. 13, 123-129
32. Hamson, E. J., Keane, F. M., Tholen, S., Schilling, O., and Gorrell, M. D. (2014) Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin. Appl. 8, 454-463
33. Keane, F. M., Yao, T. W., Seelk, S., Gall, M. G., Chowdhury, S., Poplawski, S. E., Lai, J. H., Li, Y., Wu, W., Farrell, P., Vieira de Ribeiro, A. J., Osborne, B., Yu, D. M., Seth, D., Rahman, K., Haber, P., Topaloglu, A. K., Wang, C., Thomson, S., Hennessy, A., Prins, J., Twigg, S. M., McLennan, S. V., Mc-Caughan, G. W., Bachovchin, W. W., and Gorrell, M. D. (2013) Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio 4, 43-54
34. Laverman, P., van der Geest, T., Terry, S. Y., Gerrits, D., Walgreen, B., Helsen, M. M., Nayak, T. K., Freimoser-Grundschober, A., Waldhauer, I., Hosse, R. J., Moessner, E., Umana, P., Klein, C., Oyen, W. J., Koenders, M. I., and Boerman, O. C. (2015) Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis. J. Nucl. Med. 56, 778-783
35. Yu, D. M., Yao, T. W., Chowdhury, S., Nadvi, N. A., Osborne, B., Church, W. B., McCaughan, G. W., and Gorrell, M. D. (2010) The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J. 277, 1126-1144
36. Belouski, E. J. C., Ellison, M. M., Hamburger, A. E., Hecht, R. I., Li, Y.-S, Michaels, M. L., Sun, J., and Xu, J. (2014) FGF21 polypeptides comprising two or more mutations and uses thereof. U. S. Patent 8,835,385
37. Wu, A. L., Kolumam, G., Stawicki, S., Chen, Y., Li, J., Zavala-Solorio, J., Phamluong, K., Feng, B., Li, L., Marsters, S., Kates, L., van Bruggen, N., Leabman, M., Wong, A., West, D., Stern, H., Luis, E., Kim, H. S., Yansura, D., Peterson, A. S., Filvaroff, E., Wu, Y., and Sonoda, J. (2011) Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med. 3, 113ra126
38. Jansen, K., Heirbaut, L., Verkerk, R., Cheng, J. D., Joossens, J., Cos, P., Maes, L., Lambeir, A. M., De Meester, I., Augustyns, K., and Van der Veken, P. (2014) Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). J. Med. Chem. 57, 3053-3074
39. Rawlings, N. D., Waller, M., Barrett, A. J., and Bateman, A. (2014) MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 42, D503-509
40. Edosada, C. Y., Quan, C., Tran, T., Pham, V., Wiesmann, C., Fairbrother, W., and Wolf, B. B. (2006) Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly2 -Pro1 -cleaving specificity. FEBS Lett. 580, 1581-1586
41. Bobbert, T., Schwarz, F., Fischer-Rosinsky, A., Pfeiffer, A. F., Möhlig, M., Mai, K., and Spranger, J. (2013) Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care 36, 145-149
42. Hanssen, M. J., Broeders, E., Samms, R. J., Vosselman, M. J., van der Lans, A. A., Cheng, C. C., Adams, A. C., van Marken Lichtenbelt, W. D., and Schrauwen, P. (2015) Serum FGF21 levels are associated with brown adipose tissue activity in humans. Sci. Rep. 5, 10275
43. Niedermeyer, J., Kriz, M., Hilberg, F., Garin-Chesa, P., Bamberger, U., Lenter, M. C., Park, J., Viertel, B., Püschner, H., Mauz, M., Rettig, W. J., and Schnapp, A. (2000) Targeted disruption of mouse fibroblast activation protein. Mol. Cell. Biol. 20, 1089-1094
44. Zhen, E. Y., Jin, Z., Ackermann, B. L., Thomas, M. K., and Gutierrez, J. A. (2015) Circulating FGF21 proteolytic processing mediated by fibroblast activation protein. Biochem. J. 10.1042/BJ20151085
45. Ong, K. L., Rye, K. A., O'Connell, R., Jenkins, A. J., Brown, C., Xu, A., Sullivan, D. R., Barter, P. J., Keech, A. C., and FIELD Study Investigators (2012) Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 97, 4701-4708
46. Migoya, E. M., Bergeron, R., Miller, J. L., Snyder, R. N., Tanen, M., Hilliard, D., Weiss, B., Larson, P., Gutierrez, M., Jiang, G., Liu, F., Pryor, K. A., Yao, J., Zhu, L., Holst, J. J., Deacon, C., Herman, G., Thornberry, N., Amatruda, J., Williams-Herman, D., Wagner, J. A., and SinhaRoy, R. (2010) Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin. Pharmacol. Ther. 88, 801-808
47. Levy, M. T., McCaughan, G. W., Marinos, G., and Gorrell, M. D. (2002) Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver 22, 93-101
48. Wäldele, S., Koers-Wunrau, C., Beckmann, D., Korb-Pap, A., Wehmeyer, C., Pap, T., and Dankbar, B. (2015) Deficiency of fibroblast activation protein α ameliorates cartilage destruction in inflammatory destructive arthritis. Arthritis Res. Ther. 17, 12
49. Santos, A. M., Jung, J., Aziz, N., Kissil, J. L., and Puré, E. (2009) Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 119, 3613-3625
50. Osborne, B., Yao, T. W., Wang, X. M., Chen, Y., Kotan, L. D., Nadvi, N. A., Herdem, M., McCaughan, G. W., Allen, J. D., Yu, D. M., Topaloglu, A. K., and Gorrell, M. D. (2014) A rare variant in human fibroblast activation protein associated with ER stress, loss of enzymatic function and loss of cell surface localisation. Biochim. Biophys. Acta 1844, 1248-1259
51. Agustí-Cobos, E., and Tenorio-Laranga, J. (2011) Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor alpha2-antiplasmin: a rebuttal. J. Thromb. Haemost. 9, 1266-1267; author reply 1268-1269
52. Huang, C. H., Suen, C. S., Lin, C. T., Chien, C. H., Lee, H. Y., Chung, K. M., Tsai, T. Y., Jiaang, W. T., Hwang, M. J., and Chen, X. (2011) Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate. J. Biochem. 149, 685-692